Pfizer Breast Cancer Clinical Trials

Together we can make a difference

Breast cancer is one of the most common and serious health challenges worldwide.

Pfizer has several ongoing clinical trials assessing potential therapies for patients with breast cancer, including early and advanced disease, across different disease volumes and molecular subtypes such as estrogen receptor (ER), hormone receptor (HR), and human epidermal growth factor receptor 2 (HER2).

For more information about Pfizer’s enrolling breast cancer clinical trials, please click the Learn More button below.

Pfizer’s late-stage investigational medicines for breast cancer

Atirmociclib – a highly potent CDK4 inhibitor

Oral tablet taken twice daily
Potent CDK4 inhibitor with minimal effect on CDK6
May allow higher dosing with fewer side effects
Early data shows promise in patients who progressed on previous treatments
Being tested in combination with PF-07104091 (CDK2 inhibitor) to overcome resistance

Disitamab vedotin – an antibody-drug conjugate (ADC)

Given as an IV infusion once every 2 weeks
Novel HER2-directed ADC
Delivers a microtubule inhibitor (MMAE) to tumor cells
Shown encouraging monotherapy activity in late-line HER2-expressing mBC

Prifetrastat – a KAT6A inhibitor

Oral tablet taken twice daily
Blocks KAT6A and KAT6B enzymes
Shown promise when combined with fulvestrant to overcome endocrine resistance

Do you have potentially eligible patients with advanced breast cancer in your care?

They may be eligible for one of Pfizer’s Breast Cancer Clinical Trials.

To find out more about our breast cancer investigational medicines, breast cancer clinical trials, and how to refer potentially eligible patients, please complete the Contact Form and a member of the Pfizer Field Medical team will contact you.

Contact Form

This contact form is intended to be completed by healthcare professionals only. Please DO NOT submit any patient data in the contact form.

First Name

Title

Institution

Phone number

State/Province

Last Name

Specialty

E-mail

City

Zip Code/Postal Code

Areas of Interest

Investigational Drug / MOA
Study Design
Inclusion and exclusion criteria
How to Refer to a Patient

Communication preference – select all that apply

By email
By phone

apply Communication Institution

Disclaimer

I, a healthcare professional, confirm that the information entered in the contact form is my personal information and does not include any patient data.

Disclaimer

I agree to be contacted via email or phone, as I would like to receive more information about a Pfizer breast cancer clinical trial. I have read and understood further information regarding data protection. I can revoke this consent at any time.

Disclaimer

The use of your personal data complies with applicable law and our privacy policy which can be found here.

Why refer a patient?

Clinical trials help researchers learn how safe and effective potential medical treatments are when given to us. All medicines, vaccines, and health devices approved today are first tested in hundreds to thousands of volunteers – clinical trials are essential for modern medicine to advance.

Importance of representation

Many factors, including genetics, race, age, and ethnicity, can impact how people respond to medication. That is why it is so important that clinical trials include people of all ages and backgrounds. The greater the representation among clinical trial participants, the more we can learn about potential medicines, including how they work for different people.

Pfizer Breast Cancer Clinical Trials

Together we can make a difference

Pfizer’s late-stage investigational medicines for breast cancer

Atirmociclib – a highly potent CDK4 inhibitor

Disitamab vedotin – an antibody-drug conjugate (ADC)

Prifetrastat – a KAT6A inhibitor

Do you have potentially eligible patients with advanced breast cancer in your care?

Why refer a patient?

Importance of representation

For Healthcare Professionals